Difference between revisions of "Mirtazapine-agomelatine"

From Psychiatrienet
Jump to: navigation, search
 
Line 3: Line 3:
 
| to = agomelatine  
 
| to = agomelatine  
 
| stop =  
 
| stop =  
* '''Before day 1:''' gradually reduce dosage of mirtazapine to a maximum of 30 mg/day, when this dosage is > 30 mg/day.
+
{{StopMirtazapine}}
* '''Day 1:''' reduce dosage of mirtazapine to 15 mg/day.
 
* '''Day 8:''' stop administration of mirtazapine.
 
 
| start =  
 
| start =  
 
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.
 
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.
Line 11: Line 9:
  
 
| info =  
 
| info =  
{{review}}
+
{{nointeractions}}
 
}}
 
}}

Latest revision as of 14:21, 7 October 2015

Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from mirtazapine to agomelatine.

Nietinrijdenbord.png Stop mirtazapine
  • Before day 1: Gradually reduce dosage of mirtazapine to a maximum of 30 mg/day, when this dosage is > 30 mg/day.
  • Day 1: Reduce dosage of mirtazapine to 15 mg/day.
  • Day 8: Stop administration of mirtazapine.
Eenrichtingbord.png Start agomelatine
  • Day 1: simultaneously start administration of agomelatine in a dosage of 25 mg/day.
  • Day 8: only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day. [1]
Infobord.png More information
  • No severe interactions are known.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.